Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy

Abstract

It is well-known that tamoxifen increases the risk of endometrial cancer. Although metastasis to the uterus from breast cancer is uncommon, there have been some case reports on uterine metastasis. If an endometrial abnormality is detected, the differential diagnosis of whether the uterine tumor is metastatic or primary is very important to determine the course of treatment. We herein report a case in which we detected a uterine tumor during follow-up after treatment with tamoxifen, and demonstrate that GCDFP-15 is useful in diagnosing metastatic uterine tumors arising from breast cancer.

Extracted Key Phrases

2 Figures and Tables

0200400600201220132014201520162017
Citations per Year

708 Citations

Semantic Scholar estimates that this publication has 708 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Hara2010EndometrialMF, title={Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy}, author={Fumikata Hara and Sachiko Kiyoto and Daisuke Takabatake and Seiki Takashima and Kenjiro Aogi and Shozo Ohsumi and Norihiro Teramoto and Rieko Nishimura and Shigemitsu Takashima}, year={2010} }